FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384947315> ?p ?o ?g. }

• W4384947315 abstract "<h3>Background</h3> Cryoglobulinemic Vasculitis (CV) is a rare autoimmune systemic disorder with multiple organ involvement. During the current COVID-19 pandemic, the patients with CV can accounted among frail populations because of the presence of multiple organ involvement, chronic steroid treatment, and more frequent old age. <h3>Objectives</h3> The present study aimed to investigate the prevalence and outcome of COVID-19, as well the safety and immunogenicity of COVID-19 vaccines in a wide CV cohort by a multicenter survey. <h3>Methods</h3> Patients with CV were consecutively recruited at 11 Italian referral centers. CV diagnosis, clinico-serological parameters, COVID-19 tests, and vaccination immunogenicity were carried out according to current methods. <h3>Results</h3> Four-hundred-thirty unselected CV patients (130 M; mean age 70±10.96 years) were recruited from February 2020 to October 2021. COVID-19 prevalence was significantly higher in CV patients compared to the Italian general population (11.9% vs 8.0%, p<0.005); furthermore, we observed a higher mortality in CV subjects with COVID-19 compared to those without (5.9% vs 0.5%, p<0.01). An older age (≥60 years) correlated with a worse COVID-19 outcome. Vaccine was administered in 87% of patients, and 50% received a boostering dose. Disease flares/worsening following the vaccination were significantly less frequent than those associated to COVID-19 (5% vs 14%, p=0.0012). CV patients showed an impaired vaccination immunogenicity compared to controls (p<0.05), as well an increased no-response rate after the booster. <h3>Conclusion</h3> CV patients have a higher risk to develop COVID-19, as well of more severe disease manifestations. Vaccines had a good safety profile in CV patients and of note, the vaccine-related side effects/disease flares were significantly lower compared to those COVID-19-related. However, a quarter of vaccinated individuals do not show detectable seroconversion; this is a major challenge for clinicians. Overall, a close monitoring of these frail patients during the ongoing pandemic is particularly advisable. <h3>References</h3> [1]Ferri C, et al. Ann Rheum Dis. 2020 Oct 14 doi: 10.1136/ annrheumdis-2020-219113. [2]Visentini M et al. Ann Rheum Dis. 2021 Nov 24. doi: 10.1136/ annrheumdis-2021-221248 [3]Ferri C et al. J Autoimmun. 2022 Jul;131:102866. doi: 10.1016/j <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared." @default.
• W4384947315 created "2023-07-22" @default.
• W4384947315 creator A5005467735 @default.
• W4384947315 creator A5011114134 @default.
• W4384947315 creator A5013897699 @default.
• W4384947315 creator A5013941152 @default.
• W4384947315 creator A5015866814 @default.
• W4384947315 creator A5019939650 @default.
• W4384947315 creator A5022952493 @default.
• W4384947315 creator A5027729229 @default.
• W4384947315 creator A5027998923 @default.
• W4384947315 creator A5029966387 @default.
• W4384947315 creator A5032715566 @default.
• W4384947315 creator A5033662310 @default.
• W4384947315 creator A5038828476 @default.
• W4384947315 creator A5048428887 @default.
• W4384947315 creator A5050032872 @default.
• W4384947315 creator A5054791712 @default.
• W4384947315 creator A5057155509 @default.
• W4384947315 creator A5058997816 @default.
• W4384947315 creator A5060383949 @default.
• W4384947315 creator A5061426521 @default.
• W4384947315 creator A5063173670 @default.
• W4384947315 creator A5066895977 @default.
• W4384947315 creator A5070658930 @default.
• W4384947315 creator A5074740002 @default.
• W4384947315 creator A5077708603 @default.
• W4384947315 creator A5078370156 @default.
• W4384947315 creator A5083830651 @default.
• W4384947315 creator A5085007757 @default.
• W4384947315 creator A5085916135 @default.
• W4384947315 creator A5086058111 @default.
• W4384947315 creator A5087424775 @default.
• W4384947315 date "2023-05-30" @default.
• W4384947315 modified "2023-10-11" @default.
• W4384947315 title "AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS.LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT’S POPULATION" @default.
• W4384947315 doi "https://doi.org/10.1136/annrheumdis-2023-eular.2234" @default.
• W4384947315 hasPublicationYear "2023" @default.
• W4384947315 type Work @default.
• W4384947315 citedByCount "0" @default.
• W4384947315 crossrefType "proceedings-article" @default.
• W4384947315 hasAuthorship W4384947315A5005467735 @default.
• W4384947315 hasAuthorship W4384947315A5011114134 @default.
• W4384947315 hasAuthorship W4384947315A5013897699 @default.
• W4384947315 hasAuthorship W4384947315A5013941152 @default.
• W4384947315 hasAuthorship W4384947315A5015866814 @default.
• W4384947315 hasAuthorship W4384947315A5019939650 @default.
• W4384947315 hasAuthorship W4384947315A5022952493 @default.
• W4384947315 hasAuthorship W4384947315A5027729229 @default.
• W4384947315 hasAuthorship W4384947315A5027998923 @default.
• W4384947315 hasAuthorship W4384947315A5029966387 @default.
• W4384947315 hasAuthorship W4384947315A5032715566 @default.
• W4384947315 hasAuthorship W4384947315A5033662310 @default.
• W4384947315 hasAuthorship W4384947315A5038828476 @default.
• W4384947315 hasAuthorship W4384947315A5048428887 @default.
• W4384947315 hasAuthorship W4384947315A5050032872 @default.
• W4384947315 hasAuthorship W4384947315A5054791712 @default.
• W4384947315 hasAuthorship W4384947315A5057155509 @default.
• W4384947315 hasAuthorship W4384947315A5058997816 @default.
• W4384947315 hasAuthorship W4384947315A5060383949 @default.
• W4384947315 hasAuthorship W4384947315A5061426521 @default.
• W4384947315 hasAuthorship W4384947315A5063173670 @default.
• W4384947315 hasAuthorship W4384947315A5066895977 @default.
• W4384947315 hasAuthorship W4384947315A5070658930 @default.
• W4384947315 hasAuthorship W4384947315A5074740002 @default.
• W4384947315 hasAuthorship W4384947315A5077708603 @default.
• W4384947315 hasAuthorship W4384947315A5078370156 @default.
• W4384947315 hasAuthorship W4384947315A5083830651 @default.
• W4384947315 hasAuthorship W4384947315A5085007757 @default.
• W4384947315 hasAuthorship W4384947315A5085916135 @default.
• W4384947315 hasAuthorship W4384947315A5086058111 @default.
• W4384947315 hasAuthorship W4384947315A5087424775 @default.
• W4384947315 hasBestOaLocation W43849473151 @default.
• W4384947315 hasConcept C126322002 @default.
• W4384947315 hasConcept C203014093 @default.
• W4384947315 hasConcept C22070199 @default.
• W4384947315 hasConcept C2776874634 @default.
• W4384947315 hasConcept C2779134260 @default.
• W4384947315 hasConcept C2780868729 @default.
• W4384947315 hasConcept C2780868878 @default.
• W4384947315 hasConcept C2908647359 @default.
• W4384947315 hasConcept C3008058167 @default.
• W4384947315 hasConcept C524204448 @default.
• W4384947315 hasConcept C71924100 @default.
• W4384947315 hasConcept C72563966 @default.
• W4384947315 hasConcept C8891405 @default.
• W4384947315 hasConcept C99454951 @default.
• W4384947315 hasConceptScore W4384947315C126322002 @default.
• W4384947315 hasConceptScore W4384947315C203014093 @default.
• W4384947315 hasConceptScore W4384947315C22070199 @default.
• W4384947315 hasConceptScore W4384947315C2776874634 @default.
• W4384947315 hasConceptScore W4384947315C2779134260 @default.
• W4384947315 hasConceptScore W4384947315C2780868729 @default.
• W4384947315 hasConceptScore W4384947315C2780868878 @default.
• W4384947315 hasConceptScore W4384947315C2908647359 @default.
• W4384947315 hasConceptScore W4384947315C3008058167 @default.
• W4384947315 hasConceptScore W4384947315C524204448 @default.
• W4384947315 hasConceptScore W4384947315C71924100 @default.
• W4384947315 hasConceptScore W4384947315C72563966 @default.
• W4384947315 hasConceptScore W4384947315C8891405 @default.

• next